106 related articles for article (PubMed ID: 35794181)
1. Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S.
Barbeau DJ; Martin JM; Carney E; Dougherty E; Doyle JD; Dermody TS; Hoberman A; Williams JV; Michaels MG; Alcorn JF; Paul Duprex W; McElroy AK
NPJ Vaccines; 2022 Jul; 7(1):77. PubMed ID: 35794181
[TBL] [Abstract][Full Text] [Related]
2. Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants.
Padhiar NH; Liu JB; Wang X; Wang XL; Bodnar BH; Khan S; Wang P; Khan AI; Luo JJ; Hu WH; Ho WZ
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746466
[TBL] [Abstract][Full Text] [Related]
3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Le Roux J; Lustig G; Madzivhandila M; Magugu SFJ; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
PLOS Glob Public Health; 2024; 4(4):e0002703. PubMed ID: 38603677
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Roux JL; Lustig G; Madzivhandila M; Magugu SF; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
medRxiv; 2023 Nov; ():. PubMed ID: 38045321
[TBL] [Abstract][Full Text] [Related]
6. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
PLoS Pathog; 2023 Nov; 19(11):e1011772. PubMed ID: 37943890
[TBL] [Abstract][Full Text] [Related]
7. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
medRxiv; 2023 Mar; ():. PubMed ID: 36993404
[TBL] [Abstract][Full Text] [Related]
8. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
9. Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands.
Juncker HG; Mulleners SJ; Ruhé EJM; Coenen ERM; Bakker S; van Doesburg M; Harinck JE; Rood RD; Bouhuijs JH; Oomen M; de Groot PCJM; Pajkrt PD; Korosi A; van Goudoever PJB; van Gils MJ; van Keulen BJ
EClinicalMedicine; 2022 May; 47():101393. PubMed ID: 35465077
[TBL] [Abstract][Full Text] [Related]
10. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
[TBL] [Abstract][Full Text] [Related]
11. Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273.
Grunau B; Golding L; Prusinkiewicz MA; Asamoah-Boaheng M; Armour R; Marquez AC; Jassem AN; Barakauskas V; O'Brien SF; Drews SJ; Haig S; Lavoie PM; Goldfarb DM
Microbiol Spectr; 2022 Apr; 10(2):e0270221. PubMed ID: 35254166
[TBL] [Abstract][Full Text] [Related]
12. Humoral and Cellular Responses to COVID-19 Vaccines in SARS-CoV-2 Infection-Naïve and -Recovered Korean Individuals.
Hwang JY; Kim Y; Lee KM; Jang EJ; Woo CH; Hong CU; Choi ST; Xayaheuang S; Jang JG; Ahn JH; Park H
Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214791
[TBL] [Abstract][Full Text] [Related]
13. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
14. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination.
Geers D; Sablerolles RSG; van Baarle D; Kootstra NA; Rietdijk WJR; Schmitz KS; Gommers L; Bogers S; Nieuwkoop NJ; van Dijk LLA; van Haren E; Lafeber M; Dalm VASH; Goorhuis A; Postma DF; Visser LG; Huckriede ALW; Sette A; Grifoni A; de Swart RL; Koopmans MPG; van der Kuy PHM; GeurtsvanKessel CH; de Vries RD;
iScience; 2023 Jan; 26(1):105753. PubMed ID: 36507223
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
16. The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination.
Hastert FD; Hein S; von Rhein C; Benz NI; Husria Y; Oberle D; Maier TJ; Hildt E; Schnierle BS
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632550
[TBL] [Abstract][Full Text] [Related]
17. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection.
Richardson JR; Götz R; Mayr V; Lohse MJ; Holthoff HP; Ungerer M
PLoS One; 2022; 17(4):e0266701. PubMed ID: 35468147
[TBL] [Abstract][Full Text] [Related]
19. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
20. Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice.
Mahrokhian SH; Tostanoski LH; Jacob-Dolan C; Zahn RC; Wegmann F; McMahan K; Yu J; Gebre MS; Bondzie EA; Wan H; Powers O; Ye T; Barrett J; Schuitemaker H; Barouch DH
NPJ Vaccines; 2022 Feb; 7(1):23. PubMed ID: 35197477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
